Data from a multinational clinical trial showed a first-in-class chemokine receptor antagonist maintained remission in Crohn’s disease and permitted steroid tapering during 36 weeks of maintenance therapy.

Among patients in remission at the end of induction therapy, 64% of those randomised to CCX282-B (Traficet-EN) remained in remission compared with 47% of placebo-treated patients. Analysis of all patients showed that a significantly higher proportion of patients in the CCX282-B arm were in remission at the end of the maintenance phase.

Read more.

Low-dose acetylsalicylic acid (ASA) and NSAIDs are among the most widely used medications in the adult population, and their use is expected to increase.

However, the use of low-dose ASA and NSAIDs is associated with a risk of gastrointestinal adverse effects such as peptic ulcer and related complications. NSAID’s are associated with a 20-30% risk of peptic ulceration and a 1% risk of bleeding. The corresponding risks for low dose ASA are 7-10% and 1.2% respectively.

The risk may also change according to the dose of NSAID or ASA used, the presence of helicobactor pylori and combinations of drugs.

Read more at Evidentia.